Bupropion is not FDA-approved as a standalone weight loss medication, but it does cause weight loss and is frequently prescribed off-label for that purpose. The FDA approved it for depression and smoking cessation. Where bupropion does have formal approval for weight management is in combination with naltrexone, sold under the brand name Contrave, which was approved in 2014 as a long-term obesity treatment.
That distinction matters because bupropion alone produces modest weight loss, roughly 2.8 kg (about 6 pounds) more than placebo over 6 to 12 months, while the combination with naltrexone is significantly more effective. Still, bupropion is one of very few antidepressants associated with weight loss rather than weight gain, which makes it a practical choice when someone needs treatment for both depression and excess weight.
How Bupropion Affects Appetite and Cravings
Bupropion works differently from most antidepressants. It doesn’t touch serotonin at all. Instead, it blocks the reuptake of two other brain chemicals: dopamine and norepinephrine. This means more of both stay active in the brain for longer. It’s the only available antidepressant with this specific profile.
Both dopamine and norepinephrine play critical roles in appetite regulation, feelings of satiety, and feeding behavior. Dopamine in particular drives the brain’s reward circuitry, which is why bupropion also helps reduce cravings for nicotine and food. The same anti-craving effect that makes it useful for quitting smoking appears to dampen the reward response to eating. Decreased appetite is one of the most commonly reported effects during treatment.
Weight Loss With Bupropion Alone
In a 48-week clinical trial, obese adults taking bupropion at 300 mg per day lost an average of 7.2% of their body weight by week 24 and maintained a 7.5% loss through week 48. Those on the higher 400 mg dose lost 10.1% by week 24 and held at 8.6% at 48 weeks. For someone weighing 200 pounds, that translates to roughly 15 to 17 pounds sustained over a year.
Those numbers come from a controlled trial where participants completed the full course. Real-world results vary, and the placebo-subtracted difference (the amount of weight loss you can attribute specifically to the drug rather than lifestyle changes alone) is closer to about 6 pounds over 6 to 12 months. That’s meaningful but modest compared to newer options.
The Combination With Naltrexone (Contrave)
The FDA-approved combination pairs 360 mg of bupropion with 32 mg of naltrexone daily, split into two doses. Naltrexone is an opioid blocker originally used to treat alcohol and opioid dependence. On its own, it doesn’t do much for weight. But combined with bupropion, the two drugs amplify each other’s effects on appetite-regulating brain cells.
Here’s how it works: bupropion stimulates certain neurons in the hypothalamus to release signals that suppress appetite. But those same neurons also release a compound that acts as a brake, looping back to quiet them down. Naltrexone blocks that brake. The result is a stronger, more sustained appetite-suppressing signal than bupropion can achieve on its own. Animal studies found that injecting both drugs together into the brain’s reward center reduced food intake more than either drug alone.
In clinical practice, the combination is started at one tablet daily and increased weekly over four weeks to the full dose of two tablets twice daily. This gradual ramp-up helps reduce the risk of seizures and blood pressure spikes, both known concerns with bupropion.
How It Compares to Other Weight Loss Medications
A network meta-analysis comparing the major FDA-approved weight loss medications found clear differences in effectiveness at one year:
- Semaglutide (Wegovy): 13.7% average weight loss from baseline
- Phentermine/topiramate (Qsymia): 9.1% weight loss
- Liraglutide (Saxenda): 5.0% weight loss
- Bupropion/naltrexone (Contrave): 4.6% weight loss
Bupropion/naltrexone sits at the lower end of this spectrum. Semaglutide produces roughly three times the weight loss. But these drugs differ in cost, availability, side effect profiles, and how they’re taken (oral pill vs. weekly injection), so the “best” option depends on individual circumstances. Bupropion-based treatment has the advantage of also addressing depression and nicotine cravings, which makes it a practical two-for-one for people dealing with those issues alongside excess weight.
Timeline for Seeing Results
Weight loss with bupropion, whether alone or combined with naltrexone, typically becomes noticeable within the first four weeks. In studies of the combination, measurable weight loss appeared by week four and continued through 56 weeks. A meta-analysis found that weight loss was greater in studies lasting longer than 26 weeks compared to shorter ones, suggesting the drug’s effects build over time rather than plateauing early.
Current clinical guidelines recommend using obesity medications long-term when they’re working. The 2025 Canadian obesity management guidelines specifically note that pharmacotherapy should continue to maintain weight loss and prevent regain. Stopping the medication typically leads to weight returning, which is consistent with how all current obesity drugs work.
Common Side Effects
Bupropion’s side effect profile is well established from decades of use as an antidepressant. The most commonly reported effects include dry mouth, trouble sleeping, anxiety, restlessness, trembling, and decreased appetite (which, in this context, is partly the point). Some people experience irritability, headaches, or stomach pain.
Most of these side effects tend to ease as the body adjusts over the first few weeks. The more serious concern is an increased risk of seizures, which is why the dose is titrated slowly and why bupropion is not prescribed to people with seizure disorders or eating disorders like bulimia. Blood pressure can also rise, so monitoring during treatment is standard.
Notably, bupropion does not cause the sexual side effects or weight gain common with serotonin-based antidepressants. This is one of the main reasons clinicians choose it for patients where weight is a concern.
Who Gets Prescribed Bupropion for Weight
The combination product (Contrave) is indicated for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition like high blood pressure or high cholesterol. The 2025 Canadian guidelines recommend the combination specifically for BMIs between 27 and 45.
Standalone bupropion for weight loss remains off-label, but it’s a common choice when a prescriber wants to treat depression or help with smoking cessation while avoiding the weight gain associated with other antidepressants. In that scenario, the weight loss is a beneficial side effect rather than the primary goal. For someone whose main objective is losing as much weight as possible, newer medications like semaglutide are substantially more effective, but they come with their own tradeoffs in cost and tolerability.